dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· May 11, 2026

Is Wells Fargo (WFC) Offering Opportunity After Recent Share Price Pullback?

View original at finance.yahoo.com
Is Wells Fargo (WFC) Offering Opportunity After Recent Share Price Pullback? Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Broader discussions about interest rates, credit quality and regulation continue to frame how investors assess risk and upside for large banks like Wells Fargo, explaining why share price can move without stock-specific developments

    60% confidence
  • Wells Fargo's 1-year return of 3.2% is lagging behind its large US bank peers

    60% confidence
  • The Excess Returns model uses a Stable EPS estimate of $7.91 per share based on weighted future Return on Equity estimates from 18 analysts

    60% confidence
  • Wells Fargo scores a full 6 out of 6 on Simply Wall St's valuation checks

    60% confidence
  • The Stable Book Value of $59.58 per share is sourced from weighted future Book Value estimates from 15 analysts

    60% confidence
  • Wells Fargo's Excess Returns model implies an intrinsic value of approximately $128.16 per share, indicating the stock is materially undervalued by roughly 41.0% relative to the current share price of ~$75.64

    60% confidence

Data points we hold from this source

Wells Fargo & Company · eps7.91 USD_per_share
Wells Fargo & Company · margin13.27 percent
Wells Fargo & Company · stock price75.64 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Is Wells Fargo (WFC) Offering Opportunity After Recent Share Price Pullback?: Source | Via News | fr.via.news